# Catenion London

Catenion is a specialist management consulting firm that guides pharmaceutical and biotech companies through complex strategic decisions using rigorous scientific methodology. Based in London, they serve mid-to-large biopharmaceutical organisations navigating R&D investment decisions, portfolio management, and clinical development pathways.

The firm distinguishes itself through three core strengths. First, their team comprises life science PhDs who conduct multidimensional, evidence-based assessments rather than relying on generic consulting frameworks. Second, they leverage two decades of established relationships and deep institutional knowledge across the global biopharmaceutical sector. Third, they integrate advanced data science capabilities—including bioinformaticians and computational biologists—into their analytical process, enabling quantitative rigour alongside scientific expertise.

Catenion addresses mission-critical challenges that pharmaceutical companies face: identifying which assets warrant investment, assessing technical and scientific risks within R&D programmes, evaluating therapeutic expansion opportunities, and screening potential acquisition targets. Their proprietary methodologies, including a risk assessment tool based on over 500 criteria and their ASAP screening process, provide structured, validated approaches to decision-making in environments of significant uncertainty and complexity.

Rather than offering broad-brush strategy consulting, Catenion focuses exclusively on life sciences, combining domain expertise with analytical sophistication. This specialisation makes them particularly valuable for companies seeking to differentiate clinical strategies or make high-stakes portfolio decisions based on robust scientific evidence rather than market assumptions.